AHR and cancer: Especially, development of anti-cancer AhR ligands via repurposing of FDA approved drugs and drugs that have reached testing in clinical trials whose toxicity profiles have been well characterized represents an excellent opportunity to expedite development of the AhR as a clinical drug target by addressing concerns associated with dioxin-mediated AhR activation.